Search

Your search keyword '"Mascola, John"' showing total 2,109 results

Search Constraints

Start Over You searched for: Author "Mascola, John" Remove constraint Author: "Mascola, John"
2,109 results on '"Mascola, John"'

Search Results

151. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

152. Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability

153. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

154. Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants

155. Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

156. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

158. Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses

159. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention

160. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron

162. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

164. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

165. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

167. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

168. Protection of calves by a prefusion-stabilized bovine RSV F vaccine

172. A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

173. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice

174. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys

175. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung

176. Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition

178. Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector

180. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron

181. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

182. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization

183. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates

184. Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine

185. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

186. Structure and immune recognition of trimeric pre-fusion HIV-1 Env

187. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

188. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1

189. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV

192. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor

193. EBOLA VIRUS: Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

194. Contributors

197. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

198. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

199. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

200. SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity

Catalog

Books, media, physical & digital resources